Peregrine Capital Management LLC Makes New $5.87 Million Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR

Peregrine Capital Management LLC bought a new position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 84,324 shares of the company’s stock, valued at approximately $5,865,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Ameriprise Financial Inc. lifted its holdings in Structure Therapeutics by 7.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock worth $32,939,000 after buying an additional 106,389 shares during the period. Casdin Capital LLC lifted its holdings in Structure Therapeutics by 26.9% during the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after buying an additional 330,000 shares during the period. Millennium Management LLC lifted its holdings in Structure Therapeutics by 4.5% during the 3rd quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock worth $35,687,000 after buying an additional 54,496 shares during the period. Orbimed Advisors LLC lifted its holdings in Structure Therapeutics by 49.5% during the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after buying an additional 397,272 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in Structure Therapeutics by 0.5% during the 3rd quarter. Franklin Resources Inc. now owns 745,734 shares of the company’s stock worth $20,881,000 after buying an additional 3,951 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $47.02 on Friday. The company has a market cap of $3.33 billion, a P/E ratio of -59.52 and a beta of -1.17. The stock has a 50 day simple moving average of $56.10 and a two-hundred day simple moving average of $55.01. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $15.80 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). On average, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on GPCR shares. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. HC Wainwright cut their target price on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 16th. BMO Capital Markets set a $145.00 price objective on Structure Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday. Finally, JPMorgan Chase & Co. raised their target price on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.00.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.